Ogólnoustrojowa farmakokinetyka leków anty-VEGF podawanych doszklistkowo w leczeniu wysiękowego AMD

• Authors: Marta Misiuk-Hojło , Karolina Czajor

Title variants

EN

Systemic pharmacokinetics of intravitreal anti-VEGF medications in wet AMD treatment

• Languages of publication: PL

Abstracts

PL

Nowoczesna terapia wysiękowej postaci AMD opiera się na stosowaniu leków w formie iniekcji doszklistkowych: bewacyzumabu, ranibizumabu oraz afliberceptu. Populacja osób poddanych długotrwałej ekspozycji na działanie preparatów anty-VEGF stale rośnie. Ze względu na przenikanie leków podawanych doszklistkowo do krążenia ogólnego znajomość właściwości dostępnych preparatów jest szczególnie ważna w podejmowaniu decyzji o ordynowanym leczeniu. Różnią się one między sobą budową cząsteczki, powinowactwem wiązania VEGF oraz farmakokinetyką. Ranibizumab charakteryzuje się szybkim klirensem z krążenia i krótkotrwałą ogólnoustrojową ekspozycją. Wolniejszy klirens z krążenia bewacyzumabu i afliberceptu jest związany z obecnością fragmentu Fc w budowie cząsteczki. Niezbędne są dalsze badania nad efektami obniżenia stężenia VEGF w surowicy w przebiegu długotrwałej terapii doszklistkowymi preparatami anty-VEGF, które mogą wpłynąć na podejmowane decyzje o wyborze leku i schematu dawkowania.

EN

Modern therapy of wet forms of AMD is based on administration of medications in the form of intravitreal injections: bevacizumab, ranibizumab and aflibercept. The population of people exposed to a long-term effect of anti-VEGF preparations is continuously increasing. Due to the penetration of the preparations administered intravitreously into the blood circulation, the knowledge of the activity of the available preparations is particularly important in deciding about the commissioned treatment. They differ in molecular structure, binding affinity of VEGF and pharmacokinetics. Ranibizumab is characterized by a fast clearance from circulation and a short-term systemic exposure. A slower bevacizumab and aflibercept circulation clearance is related to the presence of the Fc fragment in the molecular structure. Further research on the effects of the reduction of VEGF concentration in serum is essential in the course of a long-term anti-VEGF intravitreal preparation therapy, which may affect decisions about the administered medication and the dosing regimen.

Keywords

EN

AMD; aflibercept; anty-VEGF; bewacuzymab; farmakokinetyka; ranibizumab

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2016
• Volume: 3
• Issue: 1
• Pages: 4-10

Contributors

author

Marta Misiuk-Hojło

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

author

Karolina Czajor

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

References

• 1. Schmier JK, Levine JA. Economic impact of progression of age-related macular degeneration. US Ophthalmic Rev 2013; 6(1): 52.
• 2. Wang JJ, Mitchell P, Smith W, Cumming R. Bilateral involvement by age related maculopathy lesions in a population. Br J Ophthalmol 1998; 82(7): 743-747.
• 3. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114(2): 253-262.
• 4. Ohm J. Über die Behandlung der Netzhautablösung durch operative entleerung der subretinalen flüssigkeit und einspritzen vom luft in den glaskörper. Albrecht von Graefes Arch Ophthalmol 1911; (79): 442-450.
• 5. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol 2013; 13(6): 438-451.
• 6. Stankiewicz A. Patogeneza zwyrodnienia plamki związanego z wiekiem. Zwyrodnienie plamki związane z wiekiem – przewodnik diagnostyki i terapii. Termedia, Poznań 2010: 9-16.
• 7. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280(6): C1358-1366.
• 8. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90(11): 1344-1349.
• 9. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36(4): 331-335.
• 10. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4): 336-339.
• 11. Sun C, Klein R, Wong TY. Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 2009; 116(10): 1913-1919.
• 12. Ikram MK, Mitchell P, Klein R, et al. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke J Cereb Circ 2012; 43(6): 1681-1683.
• 13. Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow- up study. Stroke J Cereb Circ 2010; 41(4): 613-617.
• 14. Laude A, Tan LE, Wilson CG, et al. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog Retin Eye Res 2010; 29(6): 466-475.
• 15. Christoforidis JB, Carlton MM, Wang J, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 2013; 33(5): 946-952.
• 16. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013; 120(11): 2300-2309.
• 17. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5(suppl 1): S37-47.
• 18. Zhang Y, Yao Z, Kaila N, et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 2014; 121(11): 2237-2246.
• 19. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15(2): 171-185.
• 20. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6(8): 465-477.
• 21. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146(4): 508-512.
• 22. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115(10): 1750-1755.
• 23. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50(10): 4807-4813.
• 24. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114(5): 855- -859.
• 25. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep 2011; 1(1): 5.
• 26. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012; 154(4): 682-686.e2.
• 27. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114(12): 2179-2182.
• 28. Park SJ, Oh J, Kim YK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye 2015; 29(4): 561-568.
• 29. Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97(4): 454-459.
• 30. Wang X, Sawada T, Sawada O, et al. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 2014; 158(4): 738-744.e1.
• 31. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98(12): 1636-1641.
• 32. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012; 119(12): 2537-2548.
• 33. Rouvas A, Liarakos VS, Theodossiadis P, et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009; 223(6): 383-389.
• 34. Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol 2013; 7: 1591-1595.
• 35. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet Lond Engl 2013; 382(9900): 1258-1267.

• Document Type: article